The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
暂无分享,去创建一个
Andrea S. Llera | Osvaldo L. Podhajcer | Edgardo Salvatierra | O. Podhajcer | A. Llera | L. Benedetti | M. R. Girotti | Maria Romina Girotti | Federico Prada | Lorena Benedetti | F. Prada | E. Salvatierra
[1] N. Said,et al. Normalization of the Ovarian Cancer Microenvironment by SPARC , 2007, Molecular Cancer Research.
[2] N. Said,et al. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. , 2005, The American journal of pathology.
[3] Jonas S. Almeida,et al. Accurate Discrimination of Barrett's Esophagus and Esophageal Adenocarcinoma Using a Quantitative Three-Tiered Algorithm and Multimarker Real-time Reverse Transcription-PCR , 2005, Clinical Cancer Research.
[4] E. Sage,et al. Development of UV-induced squamous cell carcinomas is suppressed in the absence of SPARC. , 2004, The Journal of investigative dermatology.
[5] D. Massi,et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.
[6] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[7] Kai Stühler,et al. Tumor suppressor Smad4 mediates downregulation of the anti‐adhesive invasion‐promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a “secretome” analysis , 2004, Proteomics.
[8] Mariano J. Alvarez,et al. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. , 2005, Cancer research.
[9] Javed Khan,et al. Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers , 2005, Clinical Cancer Research.
[10] O. Podhajcer,et al. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated , 2007, International journal of cancer.
[11] E. Sage,et al. Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells , 2005, Journal of cellular physiology.
[12] M. Iruela-Arispe,et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis , 1994, The Journal of cell biology.
[13] P. Parsons,et al. Novel markers for poor prognosis in head and neck cancer , 2005, International journal of cancer.
[14] K. Wakamatsu,et al. Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels , 2005, Clinical Cancer Research.
[15] M. Colombo,et al. Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice , 2005, Journal of Cell Science.
[16] M. Mareel,et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment , 2005, Oncogene.
[17] C. Miller,et al. Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response , 2007, Genes and Immunity.
[18] H. Auer,et al. Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes , 2004, Cancer Research.
[19] J. Murphy-Ullrich. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? , 2001, The Journal of clinical investigation.
[20] R. Timpl,et al. The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. , 1995, Journal of molecular biology.
[21] V. Castronovo,et al. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.
[22] H. Juan,et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition , 2007, Oncogene.
[23] D. Bigner,et al. Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation* , 2004, Journal of Biological Chemistry.
[24] R. Moll,et al. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast , 2005, Virchows Archiv.
[25] C. Logothetis,et al. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. , 2000, Cell calcium.
[26] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[27] F. Sarkar,et al. Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. , 2004, Lung cancer.
[28] A. Nakeff,et al. SPARC Modulates Cell Growth, Attachment and Migration of U87 Glioma Cells on Brain Extracellular Matrix Proteins , 2001, Journal of Neuro-Oncology.
[29] A. Mes-Masson,et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p , 2007, Oncogene.
[30] J. Ambati,et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. , 2006, The Journal of clinical investigation.
[31] D. Fan,et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[32] C. Logothetis,et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. , 2007, Cancer research.
[33] R. Savani,et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[34] M. Reed,et al. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. , 2003, The American journal of pathology.
[35] D. Figarella-Branger,et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization , 2006, Oncogene.
[36] Mark A. Rubin,et al. Expression profiling of human renal carcinomas with functional taxonomic analysis , 2002, BMC Bioinformatics.
[37] E. Sage,et al. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.
[38] E. Sage,et al. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. Long,et al. Role of N-Linked Glycosylation in Human Osteonectin , 1995, The Journal of Biological Chemistry.
[40] P. Higgins,et al. Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. , 1993, Experimental cell research.
[41] M. Yao,et al. SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. , 2001, Human pathology.
[42] Maurice P H M Jansen,et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] C. Iacobuzio-Donahue,et al. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. , 2002, Cancer research.
[44] A. Gown,et al. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. , 2000, Gynecologic oncology.
[45] P. Bornstein. Cell-matrix interactions: the view from the outside. , 2002, Methods in cell biology.
[46] E. Sage,et al. Cell cycle‐dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix , 1999, Journal of cellular biochemistry.
[47] M. Reed,et al. Cleavage of the Matricellular Protein SPARC by Matrix Metalloproteinase 3 Produces Polypeptides That Influence Angiogenesis* , 2003, Journal of Biological Chemistry.
[48] J. Nährig,et al. Identification of gene signatures for invasive colorectal tumor cells. , 2007, Cancer detection and prevention.
[49] A. Bosserhoff,et al. Snail-regulated genes in malignant melanoma , 2005, Melanoma research.
[50] M. Reed,et al. Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC‐null mice , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[51] T. Mikkelsen,et al. Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.
[52] S. Mok,et al. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. , 2007, Neoplasia.
[53] R. Ross,et al. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Pibarot,et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis , 2006, Heart.
[55] G. Berx,et al. Unraveling signalling cascades for the Snail family of transcription factors. , 2005, Cellular signalling.
[56] T. Byzova,et al. Molecular Pathway for Cancer Metastasis to Bone* , 2003, Journal of Biological Chemistry.
[57] E. Sage,et al. SPARC antagonizes the effect of basic fibroblast growth factor on the igration of bovine aortic endothelial cells , 1992, Journal of cellular biochemistry.
[58] N. Said,et al. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. , 2007, The American journal of pathology.
[59] T. Takano,et al. Quantitative analysis of osteonectin mRNA in thyroid carcinomas. , 2002, Endocrine journal.
[60] M. Reed,et al. Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. , 2000, Kidney international.
[61] P. Chambon,et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.
[62] E. Sage,et al. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin‐like region and the Ca2+‐binding EF‐hand , 1995, Journal of cellular biochemistry.
[63] A. Albini,et al. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells , 2006, British Journal of Cancer.
[64] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[65] J. Squire,et al. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma , 2006, BMC Cancer.
[66] K. Mimori,et al. Prognostic score of gastric cancer determined by cDNA microarray. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] P. Bornstein,et al. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.
[68] H. Kleinman,et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. , 2005, Cancer research.
[69] S. Rempel,et al. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. , 2000, International journal of oncology.
[70] C. Gutschow,et al. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. , 2006, Oncology reports.
[71] G. Finocchiaro,et al. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME , 2007, Nucleic acids research.
[72] M. Iruela-Arispe,et al. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.
[73] Z. Werb,et al. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway , 1993, The Journal of cell biology.
[74] Peter Schirmacher,et al. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. , 2007, Neoplasia.
[75] T. Yeatman,et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer , 2007, Genome Biology.
[76] 강현주,et al. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers , 2007 .
[77] M. Webber,et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. , 1999, Cancer research.
[78] H. Kanayama,et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. , 2001, The Journal of urology.
[79] K. Klinger,et al. Alterations in Vascular Gene Expression in Invasive Breast Carcinoma , 2004, Cancer Research.
[80] J. D. Vos,et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.
[81] Kornelia Polyak,et al. Molecular markers in ductal carcinoma in situ of the breast. , 2003, Molecular cancer research : MCR.
[82] Y. Miyagi,et al. Stimulation of Motility of Human Renal Cell Carcinoma by SPARC/Osteonectin/BM-40 Associated with Type IV Collagen , 1999, Invasion and Metastasis.
[83] M. Benito,et al. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. , 2007, Oncology reports.
[84] Gema Moreno-Bueno,et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. , 2006, Cancer research.
[85] Qiwei Yang,et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix , 2006, International journal of cancer.
[86] E Helene Sage,et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.
[87] S Hsueh,et al. Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance , 2004, British Journal of Cancer.
[88] M. Colombo,et al. Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.
[89] L. Coussens,et al. Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.
[90] M. Ringuette,et al. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. , 1999, Gynecologic oncology.
[91] P. Pavasant,et al. The synergistic effect of TGF-beta and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. , 2003, Archives of oral biology.
[92] O. Podhajcer,et al. Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth , 2006, Molecular Cancer Therapeutics.
[93] S. Ethier,et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. , 2001, Cancer research.
[94] P. Chambon,et al. Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours , 1996 .
[95] E. Sage,et al. SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[96] A. Galloway,et al. VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis , 2006, Proceedings of the National Academy of Sciences.
[97] M. Castellazzi,et al. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells , 2002, Oncogene.
[98] Yajun Yi,et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.
[99] J. Casal,et al. Proteomics-based Validation of Genomic Data , 2006, Molecular & Cellular Proteomics.
[100] T. Sørlie,et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.
[101] D. Bigner,et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases , 2007, Oncogene.
[102] M. Reed,et al. TGF‐β1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors , 1994 .
[103] O. Volpert,et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. , 2002, Cancer research.
[104] W. Stolz,et al. Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes , 2003, Experimental dermatology.
[105] G. Watkins,et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.
[106] B. Ballermann,et al. Inhibition of Capillary Morphogenesis and Associated Apoptosis by Dominant Negative Mutant Transforming Growth Factor-β Receptors (*) , 1995, The Journal of Biological Chemistry.
[107] O. Podhajcer,et al. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. , 2007, The Journal of investigative dermatology.
[108] B. le Bail,et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma , 1999, The Journal of pathology.
[109] Brian Bierie,et al. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.
[110] Julie A. Wilkins,et al. Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice , 2007, Gut.
[111] Klaus Pantel,et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.
[112] Zhihua Liu,et al. The differential expression of SPARC in esophageal squamous cell carcinoma. , 2006, International journal of molecular medicine.
[113] Alan Mackay,et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.
[114] A. Olshen,et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma , 2003, British journal of haematology.
[115] T. Sasaki,et al. Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. , 1999, Matrix biology : journal of the International Society for Matrix Biology.
[116] T. Springer,et al. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. , 1995, Immunity.
[117] T. Springer,et al. Modulation of Endothelial Cell Adhesion by Hevin, an Acidic Protein Associated with High Endothelial Venules (*) , 1996, The Journal of Biological Chemistry.
[118] G. Bratthauer,et al. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases. , 1999, Human pathology.
[119] N. Lemke,et al. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.
[120] J. Tonn,et al. Targeting angiogenesis inhibits tumor infiltration and expression of the pro‐invasive protein SPARC , 2000, International journal of cancer.
[121] T. Fujita,et al. Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor Modulate Osteocalcin and Osteonectin/SPARC Syntheses in Vitamin-D-activated Pulp Cells , 2001, Journal of dentistry research.
[122] M. Mori,et al. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression , 2003, Cancer.
[123] Nerea Martínez,et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.
[124] William P Schiemann,et al. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.
[125] M. Iruela-Arispe,et al. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. , 1995, Molecular biology of the cell.
[126] W. Frankel,et al. Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer , 2006, Annals of Surgical Oncology.
[127] O. Podhajcer,et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.
[128] P. Abbe,et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. , 2006, Cancer research.
[129] R. Brekken,et al. SPARC, a matricellular protein: at the crossroads of cell-matrix. , 2000, Matrix biology : journal of the International Society for Matrix Biology.
[130] J. Wrana,et al. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. , 1991, European journal of biochemistry.
[131] Zhihua Liu,et al. Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray , 2004, Oncogene.
[132] R. Timpl,et al. Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). , 1997, The Biochemical journal.
[133] R. Berkowitz,et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.
[134] A. Gown,et al. Distribution of SPARC in normal and neoplastic human tissue. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[135] D. Milewicz,et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor β1 in cultured normal human fibroblasts , 2005 .
[136] Orit Pappo,et al. Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays , 2002, Molecular carcinogenesis.
[137] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[138] A. Sánchez-Aguilera,et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.
[139] M. Ringuette,et al. Novel Functions of the Matricellular Proteins Osteopontin and Osteonectin/SPARC , 2002, Connective tissue research.
[140] R. Berkowitz,et al. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.
[141] D. Milewicz,et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. , 2005, Arthritis and rheumatism.
[142] A. Raz,et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells , 2007, Neuroscience Letters.
[143] O. Podhajcer,et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.
[144] Francisco Portillo,et al. The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.
[145] R. Hruban,et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.
[146] S. Cohn,et al. SPARC enhances tumor stroma formation and prevents fibroblast activation , 2007, Oncogene.
[147] S. Rempel,et al. SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[148] L. Hood,et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. , 1998, Cancer research.
[149] M. West,et al. Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.
[150] B. Nordlinger,et al. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[151] C. Vaziri,et al. The Novel SPARC Family Member SMOC-2 Potentiates Angiogenic Growth Factor Activity* , 2006, Journal of Biological Chemistry.
[152] J. Koblinski,et al. Roles of osteonectin in the migration of breast cancer cells into bone , 2006, Journal of cellular biochemistry.
[153] Qiwei Yang,et al. Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC , 2004, Cancer Research.
[154] D. Owen,et al. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. , 2005, The Journal of clinical investigation.
[155] D. Bigner,et al. Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model* , 2003, The Journal of Biological Chemistry.
[156] G. Geiss,et al. Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[157] C. Gondi,et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. , 2006, International journal of oncology.
[158] C. Iacobuzio-Donahue,et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[159] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[160] David Yang,et al. Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.
[161] H. Friess,et al. Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells , 2005, Annals of surgery.
[162] M. Quintanilla,et al. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. , 2003, The Journal of biological chemistry.
[163] E. Sage,et al. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. , 1999, Molecular biology of the cell.
[164] P. Schraml,et al. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. , 1998, Cancer research.
[165] J. Neefs,et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation , 2000, British Journal of Cancer.
[166] T. Mikkelsen,et al. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. , 1998, Journal of neuropathology and experimental neurology.
[167] B. Gardiner,et al. Osteonectin downregulates E‐cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype , 2007, International journal of cancer.
[168] M. Tang,et al. Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy , 2007, Molecular Cancer Therapeutics.
[169] M. Kurrer,et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. , 2000, Cancer research.
[170] J. Foidart,et al. Induction of SPARC by VEGF in human vascular endothelial cells. , 2001, Biochemical and biophysical research communications.
[171] E. Sage,et al. SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.
[172] M. Tang,et al. A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers* , 2007, Journal of Biological Chemistry.
[173] R. Moll,et al. CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder , 2007, Virchows Archiv.
[174] B. Sikic,et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein , 2006, Leukemia.
[175] M. Gioia,et al. Effect of Ukrain on matrix metalloproteinase-2 and Secreted Protein Acidic and Rich in Cysteine (SPARC) expression in human glioblastoma cells , 2006, Anti-cancer drugs.
[176] D. Barash,et al. In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions , 2007, BMC Genomics.
[177] M. Herlyn,et al. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. , 2002, Cancer research.
[178] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[179] W. Couser,et al. SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.
[180] V. Castronovo,et al. Evidence that breast cancer associated microcalcifications are mineralized malignant cells. , 1998, International journal of oncology.
[181] R. Brekken,et al. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.
[182] E. Thompson,et al. Doxycycline-Inducible Expression of SPARC/ Osteonectin/ BM40 in MDA-MB-231 Human Breast Cancer Cells Results in Growth Inhibition , 2002, Breast Cancer Research and Treatment.
[183] J. Graham,et al. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. , 1997, European journal of cancer.
[184] Jean-Michel,et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. , 1998, Cancer research.
[185] S. Fan,et al. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma , 2006, The Journal of pathology.
[186] R. Brekken,et al. SPARC regulates TGF‐beta1‐dependent signaling in primary glomerular mesangial cells , 2004, Journal of cellular biochemistry.
[187] G. Watkins,et al. γ-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells , 2005 .
[188] P. Marjoram,et al. The Molecular Signature of Normal Squamous Esophageal Epithelium Identifies the Presence of a Field Effect and Can Discriminate between Patients with Barrett's Esophagus and Patients with Barrett's-Associated Adenocarcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.
[189] Neil O. Carragher,et al. The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.
[190] S. Rempel,et al. cDNA Array Analysis of SPARC-modulated Changes in Glioma Gene Expression , 2002, Journal of Neuro-Oncology.
[191] O. Podhajcer,et al. Proteomic analysis identified N‐cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells , 2007, Proteomics.
[192] Stefanie S Jeffrey,et al. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue , 2004, BMC Genomics.
[193] Yoshiyuki Sakaki,et al. Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. , 2002, Cancer letters.
[194] E. Sage,et al. Regulation of interactions between cells and extracellular matrix: a command performance on several stages. , 2001, The Journal of clinical investigation.
[195] M. Paulsson,et al. Characterization of SMOC-2, a modular extracellular calcium-binding protein. , 2003, The Biochemical journal.
[196] R L Vessella,et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.